DGI
TVRD

Disciplined Growth Investors’s Tvardi Therapeutics TVRD Stock Holding History

Disciplined Growth Investors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,918
Closed -$343K – 68
2024
Q3 		$343K Sell
30,918
-22,852
-42% -$268K 0.01% 64
2024
Q2 		$499K Buy
53,770
+3,352
+7% +$80K 0.01% 61
2024
Q1 		$1.65M Buy
50,418
+82
+0.2% +$2.13K 0.03% 63
2023
Q4 		$1.35M Buy
50,336
+1,103
+2% +$45.7K 0.03% 61
2023
Q3 		$2.98M Buy
49,233
+227
+0.5% +$21.3K 0.07% 58
2023
Q2 		$4.99M Buy
49,006
+884
+2% +$122K 0.11% 55
2023
Q1 		$8.51M Buy
48,122
+276
+0.6% +$92.4K 0.22% 51
2022
Q4 		$18.5M Buy
47,846
+617
+1% +$234K 0.47% 41
2022
Q3 		$15.9M Buy
47,229
+39
+0.1% +$14.1K 0.44% 45
2022
Q2 		$15.5M Buy
47,190
+125
+0.3% +$43.9K 0.42% 48
2022
Q1 		$20.6M Buy
47,065
+1,041
+2% +$427K 0.45% 48
2021
Q4 		$20.2M Sell
46,024
-340
-0.7% -$171K 0.41% 49
2021
Q3 		$25.8M Buy
46,364
+27,618
+147% +$13.9M 0.51% 49
2021
Q2 		$9.63M Buy
18,746
+2,260
+14% +$1.43M 0.18% 62
2021
Q1 		$12.9M Sell
16,486
-2,678
-14% -$1.83M 0.26% 56
2020
Q4 		$10.4M Sell
19,164
-1,207
-6% -$633K 0.2% 60
2020
Q3 		$9.33M Buy
20,371
+28
+0.1% +$16.3K 0.22% 59
2020
Q2 		$12.5M Sell
20,343
-672
-3% -$371K 0.3% 58
2020
Q1 		$9.99M Sell
21,015
-2,288
-10% -$1.24M 0.23% 58
2019
Q4 		$13.5M Buy
23,303
+1
+0% +$702 0.22% 60
2019
Q3 		$15.3M Buy
23,302
+16
+0.1% +$13.3K 0.28% 57
2019
Q2 		$18M Sell
23,286
-405
-2% -$285K 0.34% 53
2019
Q1 		$16.7M Buy
23,691
+153
+0.7% +$91.6K 0.29% 53
2018
Q4 		$11M Sell
23,538
-64
-0.3% -$41.3K 0.23% 62
2018
Q3 		$20.4M Sell
23,602
-239
-1% -$173K 0.34% 52
2018
Q2 		$16.4M Sell
23,841
-36
-0.2% -$18.3K 0.3% 55
2018
Q1 		$10.6M Sell
23,877
-46
-0.2% -$22.3K 0.21% 60
2017
Q4 		$10.5M Buy
23,923
+335
+1% +$153K 0.21% 61
2017
Q3 		$11.6M Sell
23,588
-747
-3% -$374K 0.24% 59
2017
Q2 		$13.5M Sell
24,335
-14
-0.1% -$8.88K 0.28% 57
2017
Q1 		$16.1M Sell
24,349
-321
-1% -$171K 0.36% 57
2016
Q4 		$8.25M Buy
+24,670
New +$7.92M 0.19% 62

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Disciplined Growth Investors's TVRD Position: Q4 2024 in Review

Disciplined Growth Investors sold out of Tvardi Therapeutics (TVRD) in Q4 2024, closing a stake of 30,918 shares — an estimated $343K sold.

Disciplined Growth Investors first reported a position in TVRD in Q4 2016 and held it in 32 quarters. The position peaked at $25.8M in Q3 2021. 43 funds tracked by Wall St. Rank hold TVRD as of Q4 2024.

  • Disciplined Growth Investors reported no remaining Tvardi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Disciplined Growth Investors sold 30,918 Tvardi Therapeutics shares in Q4 2024, an estimated $343K.
  • Disciplined Growth Investors first reported a position in Tvardi Therapeutics in Q4 2016 and held it in 32 quarters.
  • Disciplined Growth Investors's Tvardi Therapeutics position peaked at $25.8M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2024.

Based on Disciplined Growth Investors's 13F filing for Q4 2024, filed 14 Feb 2025.